Non-invasive Visualization of Liver Fibrosis with [68Ga]ga-Dota-fapi-04 PET from Preclinical Insights to Clinical Translation

Yangmeihui Song,Chunxia Qin,Yixiong Chen,Weiwei Ruan,Yongkang Gai,Wenyu Song,Yu Gao,Wenzhu Hu,Pengxin Qiao,Xiangming Song,Xiaoying Lv,Danzha Zheng,Huikuan Chu,Dawei Jiang,Ling Yang,Xiaoli Lan

DOI: https://doi.org/10.1007/s00259-024-06773-z

2024-01-01

Abstract:The reversibility of early liver fibrosis highlights the need for improved early detection and monitoring techniques. Fibroblast activation protein (FAP) is a promising theranostics target significantly upregulated during fibrosis. This preclinical and preliminary clinical study investigated a FAP-targeted probe, gallium-68-labeled FAP inhibitor 04 ([68Ga]Ga-DOTA-FAPI-04), for its capability to visualize liver fibrosis. The preclinical study employed [68Ga]Ga-DOTA-FAPI-04 micro-positron emission tomography (PET)/computed tomography (CT) on carbon tetrachloride-induced mice model (n = 34) and olive oil-treated control group (n = 26), followed by validation of the probe's biodistribution. Hepatic uptake was correlated with fibrosis and inflammation levels, quantified through histology and serum assays. FAP and α-smooth muscle actin expression were determined by immunohistochemistry, as well as immunofluorescence. The subsequent clinical trial enrolled 26 patients with suspected or confirmed liver fibrosis to undergo [68Ga]Ga-DOTA-FAPI-04 PET/magnetic resonance imaging or PET/CT. Key endpoints included correlating [68Ga]Ga-DOTA-FAPI-04 uptake with histological inflammation grades and fibrosis stages, and evaluating its diagnostic and differential efficacy compared to established serum markers and liver stiffness measurement (LSM). [68Ga]Ga-DOTA-FAPI-04 mean uptake in mice livers was notably higher than in control mice, increasing from week 6 [0.70 ± 0.11 percentage injected dose per cubic centimeter ( https://clinicaltrials.gov/study/NCT04605939